Catalent (CTLT) Tops Q1 EPS by 5c, Revenues Beat; Raises FY21 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Catalent, Inc. Reports First Quarter Fiscal 2021 Results
November 3, 2020 7:15 AM ESTÂ Q1'21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1'20. On an organic basis, constant currency net revenue in Q1'21 grew 20% compared to Q1'20. Â Q1'21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or 35% in constant currency, compared to Q1'20. Q1'21 Biologics segment net revenue of $377.1 million doubled compared to Q1'20. Net debt leverage of 2.6x as of September 30; more than $1 billion in cash and cash equivalents on-hand at September 30. Increased... More



